These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15273060)

  • 21. [Diabetes and hypertension. Results from the ADVANCE study].
    Mehlsen J
    Ugeskr Laeger; 2008 Feb; 170(7):531-2. PubMed ID: 18291082
    [No Abstract]   [Full Text] [Related]  

  • 22. Getting to the heart of diabetes. Move over, blood sugar. In the fight against diabetes, it's time to focus on managing cholesterol problems and blood pressure, too.
    Harv Heart Lett; 2004 Sep; 15(1):1-2. PubMed ID: 15381493
    [No Abstract]   [Full Text] [Related]  

  • 23. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].
    Seufert J
    Dtsch Med Wochenschr; 2008 May; 133(20):1068-70. PubMed ID: 18461525
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of lipid management in diabetes.
    Ganda OP
    Cardiol Clin; 2005 May; 23(2):153-64, vi. PubMed ID: 15694744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preventing type 2 diabetes complications: from evidence-based recommendations to patient-based reality].
    Beer S; Kunz GA; Ruiz J
    Rev Med Suisse; 2005 Jun; 1(22):1492-8. PubMed ID: 16025888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
    Nellemann B; Gormsen LC; Dollerup J; Schmitz O; Mogensen CE; Rasmussen LM; Nielsen S
    Diabetes Care; 2007 Dec; 30(12):3122-4. PubMed ID: 17804683
    [No Abstract]   [Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
    Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL; ;
    Diabetes Care; 2008 Apr; 31(4):811-22. PubMed ID: 18375431
    [No Abstract]   [Full Text] [Related]  

  • 30. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 32. Diabetes resources. Getting involved in clinical trials.
    Dairman T
    Diabetes Self Manag; 2004; 21(6):87-9. PubMed ID: 15688471
    [No Abstract]   [Full Text] [Related]  

  • 33. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 37. Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization.
    Nau DP; Mallya U
    Am J Manag Care; 2005 Feb; 11(2):69-73. PubMed ID: 15726854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular therapies and their role in diabetic eye disease.
    Denniston AK; Banerjee S; Gibson JM; Dodson PM
    Diabet Med; 2005 May; 22(5):665-6. PubMed ID: 15842530
    [No Abstract]   [Full Text] [Related]  

  • 39. [Good prevention of type 2 diabetes with lipid-lowering statin therapy. Intervention studies support active treatment of risk patients].
    Nilsson PM; Attvall S; Båvenholm P
    Lakartidningen; 2004 Nov; 101(47):3798, 3801-2, 3804. PubMed ID: 15609534
    [No Abstract]   [Full Text] [Related]  

  • 40. Glycaemic control in Type 2 diabetes--not for sidelining.
    Narendran P
    Diabet Med; 2008 Jun; 25(6):639-42. PubMed ID: 18544100
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.